Meta-analysis on immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults aged above 18 years

Abstract

Objective To evaluate the immunogenicity and safety of inactivated quadrivalent influenza vaccine (QIV) in adults aged above 18 years. Methods The random control trials (RCT) in adults aged above 18 years for comparing and analyzing the immunogenicity and safety between QIV and trivalent influenza vaccine (TIV) were searched in major online databases including National Center for Biotechnology Information (NCBI) , Cochrane Library (CL) , China Biology Medicine disc (CBMd) , China National Knowledge Infrastructure (CNKI) and Wanfang Database. Sero-protection rate (SPR) , sero-conversion rate (SCR) against H1N1, H3N2, B/Victoria, B/Yamagata and incidence rate of adverse events with an interval of 21 days after vaccination were considered as endpoints and relative risk (RR) of SPR, SCR and incidence rate of adverse effect was combined. Results A total of 5 studies were enrolled. The meta-analysis result showed that pooled RRs for SPR and SCR of B/Yamagata were 1.12 (95%CI: 1.02-1.22) and 2.11 (95%CI: 1.51-2.95) , respectively; while pooled RRs for SPR and SCR of B/Victoria were 1.14 (95% CI: 1.03-1.25) and 1.78 (95% CI: 1.24-2.55) , respectively. Compared to TIV with B/Yamagata, injection site pain was more common for QIV, with a pooled RR of 1.23 (95%CI: 1.05-1.44) . Conclusions In adults aged above 18 years, QIV has the similar immunogenic effect and safety with TIV, and a superior immunogenic effect to the vaccine strain that is not included in TIV. Key words: Vaccines, inactivated; Influenza virus; Immunogenicity; Safety; Meta-analysis